AU2021395736A1 - Rna manufacturing - Google Patents

Rna manufacturing Download PDF

Info

Publication number
AU2021395736A1
AU2021395736A1 AU2021395736A AU2021395736A AU2021395736A1 AU 2021395736 A1 AU2021395736 A1 AU 2021395736A1 AU 2021395736 A AU2021395736 A AU 2021395736A AU 2021395736 A AU2021395736 A AU 2021395736A AU 2021395736 A1 AU2021395736 A1 AU 2021395736A1
Authority
AU
Australia
Prior art keywords
rna
functional analog
triphosphate
utp
gtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021395736A
Other languages
English (en)
Other versions
AU2021395736A9 (en
Inventor
Stephanie FESSER
Andreas Kuhn
Thomas ZIEGENHALS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of AU2021395736A1 publication Critical patent/AU2021395736A1/en
Publication of AU2021395736A9 publication Critical patent/AU2021395736A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2021395736A 2020-12-09 2021-12-07 Rna manufacturing Pending AU2021395736A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123465P 2020-12-09 2020-12-09
US63/123,465 2020-12-09
US202063132473P 2020-12-30 2020-12-30
US63/132,473 2020-12-30
PCT/EP2021/084488 WO2022122689A1 (en) 2020-12-09 2021-12-07 Rna manufacturing

Publications (2)

Publication Number Publication Date
AU2021395736A1 true AU2021395736A1 (en) 2023-07-27
AU2021395736A9 AU2021395736A9 (en) 2024-05-16

Family

ID=79287682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021395736A Pending AU2021395736A1 (en) 2020-12-09 2021-12-07 Rna manufacturing

Country Status (10)

Country Link
US (1) US20240110214A1 (enExample)
EP (1) EP4259161A1 (enExample)
JP (1) JP2023552468A (enExample)
KR (1) KR20230129432A (enExample)
AU (1) AU2021395736A1 (enExample)
CA (1) CA3201552A1 (enExample)
IL (1) IL303457A (enExample)
MX (1) MX2023006126A (enExample)
TW (1) TW202237844A (enExample)
WO (1) WO2022122689A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
AU2022282559A1 (en) * 2021-05-26 2024-01-04 Etherna Immunotherapies Nv Method to reduce double stranded rna by-product formation
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
JP2026506504A (ja) * 2023-02-01 2026-02-25 ジェンスクリプト ユーエスエー インク インビトロ転写方法及びそのための化合物
WO2024232914A1 (en) * 2023-05-05 2024-11-14 Trilink Biotechnologies, Llc In vitro transcription method
WO2025170909A1 (en) * 2024-02-05 2025-08-14 The Broad Institute, Inc. Nucleic acids with region-specific modifications and methods of making the same
WO2025223684A1 (en) * 2024-04-23 2025-10-30 BioNTech SE Methods and compositions for stimulating immune response

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008626A1 (en) 1993-09-20 1995-03-30 The Regents Of The University Of Colorado Strategy for the production of rna from immobilized templates
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
CN104072561B (zh) 2007-06-19 2017-12-22 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
EP3155129B1 (en) * 2014-06-10 2019-01-16 CureVac AG Method for enhancing rna production
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
CN120842296A (zh) 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN116144626A (zh) 2016-01-13 2023-05-23 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
US10337051B2 (en) * 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use

Also Published As

Publication number Publication date
US20240110214A1 (en) 2024-04-04
MX2023006126A (es) 2023-07-28
TW202237844A (zh) 2022-10-01
EP4259161A1 (en) 2023-10-18
AU2021395736A9 (en) 2024-05-16
JP2023552468A (ja) 2023-12-15
WO2022122689A1 (en) 2022-06-16
CA3201552A1 (en) 2022-06-16
KR20230129432A (ko) 2023-09-08
IL303457A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US20240110214A1 (en) Rna manufacturing
JP2023164537A (ja) Ｒｎａ癌ワクチン
US12305210B2 (en) In vitro transcription technologies
US12496561B2 (en) Vortex mixers and associated methods, systems, and apparatuses thereof
WO2024015890A1 (en) Norovirus mrna vaccines
US20240301433A1 (en) Non-natural 5'-untranslated region and 3'-untranslated region and use thereof
KR20190026670A (ko) 릴랙신을 인코딩하는 폴리뉴클레오타이드
WO2016201377A1 (en) Targeted adaptive vaccines
KR20230020991A (ko) 최적화된 뉴클레오티드 서열의 생성
US12215317B2 (en) Acetylated ribonucleic acids and uses thereof
US20250250626A1 (en) Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
CN116744941A (zh) Rna制造
CN121443738A (zh) 用于控制体内递送构建体的表达的miRNA
WO2024083345A1 (en) Methods and uses associated with liquid compositions
HK40110698A (zh) 体外转录技术
US12618064B2 (en) Acetylated ribonucleic acids and uses thereof
WO2025029700A1 (en) Vlp enteroviral vaccines

Legal Events

Date Code Title Description
SREP Specification republished